Neoadjuvant Chemotherapy for Breast Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 April 2025 | Viewed by 2143
Special Issue Editor
Interests: breast cancer treatment; biomarker development; surgical oncology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
One of the scientific backgrounds of neoadjuvant chemotherapy is the hypothesis that earlier treatment with the eradication of subclinical micrometastasis will improve survival. The pioneering clinical trials by the I-SPY2 working group have successfully identified the therapeutic agents through pCR improvement and established the "response predictor subtype".
Still, there are a lot of unresolved issues regarding the neoadjuvant chemotherapy of breast cancer, such as the predictor of pCR, the best sequence of the therapeutic regimen, the effective treatment of non-pCR patients, the role of conventional chemotherapy in terms of immunological effect, de-escalation after pCR, and escalation therapy for non-pCR. To breast surgeons, the extent of breast surgery and the efficacy of sentinel node biopsy after NAC and the best strategy for axillary management after nodal pCR are still controversial.
Through the Special Issue titled "Neoadjuvant Chemotherapy for Breast Cancer" of Cancers, all experts in this field are invited to contribute and submit their papers in an attempt to resolve the above issues.
Dr. Shin-Cheh Chen
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- breast cancer
- neoadjuvant chemotherapy
- molecular subtype
- response predictor
- survival surrogate
- immune checkpoint inhibitor
- pathological complete response
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
